-+ 0.00%
-+ 0.00%
-+ 0.00%

BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

Benzinga·08/19/2026 09:30:53
語音播報
BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.